|
|
Article: Advanced Life Meets Endpoint In First Pivotal Trial Of Antibiotic.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
The first of two Phase III pivotal trials of cethromycin from Advanced Life Sciences Holdings Inc. in community-acquired pneumonia met its primary endpoint of non-inferior cure rates compared to an approved antibiotic.
The endpoint was met despite the comparator agent, Abbott Laboratories' macrolide antibiotic Biaxin (clarithromycin), demonstrating a clinical cure rate of 95.9 percent, which Advanced Life officials said was the highest ever reported with that drug. Historically, Biaxin's clinical cure rate is between 89 percent and 91 percent, said Advanced Life President John Flavin.
The clinical rate for cethromycin, a ketolide ...
Related newspaper, magazine, and journal articles:
|
|
Article: Flavin: I quit; Resignation: DCCs Jim Flavin.
The Daily Mail (London, England);
May 28, 2008 ;
700+ words
...Byline: Alan Sherry BUSINESSMAN Jim Flavin has resigned from his position as executivechairman ... Last July the Supreme Court found that Mr Flavin had insider information onFyffes when ... profit of ?85million in February 2000. Mr Flavin was a director with Fyffes at the time ...
|
|